SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Zeneca Group plc (NYSE ticker ZEN)

No earlier versions found for this Subject.


Return to Zeneca Group plc (NYSE ticker ZEN)
 
Zeneca is in the news today with a big National Cancer Institute
study showing that women given tamoxifen citrate (tradename Nolvadex)
were 45 percent less likely to develop breast cancer than women who received placebo.

Further discussion on trading ZEN is welcomed.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News